MA30526B1 - Inhibiteurs de prolyle hydroxylase - Google Patents

Inhibiteurs de prolyle hydroxylase

Info

Publication number
MA30526B1
MA30526B1 MA31501A MA31501A MA30526B1 MA 30526 B1 MA30526 B1 MA 30526B1 MA 31501 A MA31501 A MA 31501A MA 31501 A MA31501 A MA 31501A MA 30526 B1 MA30526 B1 MA 30526B1
Authority
MA
Morocco
Prior art keywords
prolyl hydroxylase
hydroxylase inhibitors
pyrimidinetrione
hif
antagonists
Prior art date
Application number
MA31501A
Other languages
English (en)
Inventor
Kevin J Duffy
Duke M Fitch
Jian Jin
Ronggang Liu
Antony N Shaw
Kenneth Wiggall
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA30526B1 publication Critical patent/MA30526B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention décrite ici concerne certains dérivés de glycine N-substitués à fonction pyrimidinetrione de formule (I) qui sont des antagonistes des HIF-prolyl-hydroxylases et qui sont utiles pour le traitement de maladies bénéficiant de l'inhibition d'une telle enzyme, par exemple de l'anémie.
MA31501A 2006-06-23 2008-12-24 Inhibiteurs de prolyle hydroxylase MA30526B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80560206P 2006-06-23 2006-06-23

Publications (1)

Publication Number Publication Date
MA30526B1 true MA30526B1 (fr) 2009-06-01

Family

ID=38834409

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31501A MA30526B1 (fr) 2006-06-23 2008-12-24 Inhibiteurs de prolyle hydroxylase

Country Status (31)

Country Link
US (10) US8324208B2 (fr)
EP (1) EP2037922B9 (fr)
JP (1) JP5203361B2 (fr)
KR (1) KR101411816B1 (fr)
CN (1) CN101505752B (fr)
AR (1) AR061570A1 (fr)
AU (1) AU2007260837B2 (fr)
BR (1) BRPI0713446B8 (fr)
CA (1) CA2655491C (fr)
CR (1) CR10534A (fr)
DK (1) DK2037922T3 (fr)
EA (1) EA018220B1 (fr)
ES (1) ES2453100T3 (fr)
HK (1) HK1130671A1 (fr)
HR (1) HRP20140306T1 (fr)
IL (1) IL196070A (fr)
JO (1) JO2934B1 (fr)
MA (1) MA30526B1 (fr)
MX (1) MX2009000165A (fr)
MY (1) MY149861A (fr)
NO (1) NO342019B1 (fr)
NZ (1) NZ573698A (fr)
PE (1) PE20080209A1 (fr)
PL (1) PL2037922T3 (fr)
PT (1) PT2037922E (fr)
SG (1) SG174775A1 (fr)
SI (1) SI2037922T1 (fr)
TW (1) TWI394747B (fr)
UA (1) UA100225C2 (fr)
WO (1) WO2007150011A2 (fr)
ZA (1) ZA200810602B (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1868616A2 (fr) * 2005-03-29 2007-12-26 The University of Maryland, Baltimore Inhibiteurs pour domaines recepteurs de kinase regulee au moyen d'un signal extra-cellulaire, et leurs utilisations
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
AR061570A1 (es) * 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto
EP2327696A1 (fr) 2006-06-26 2011-06-01 Warner Chilcott Company, LLC Inhibiteurs de la prolyl hydroxylase et procédés d'utilisation
GB0622472D0 (en) * 2006-11-10 2006-12-20 Addex Pharmaceuticals Sa Novel heterocyclic derivatives
CA2672656C (fr) 2006-12-18 2012-03-20 Amgen Inc. Composes de naphtalenone presentant une activite inhibititrice de prolyle hydroxylase, compositions et utilisations de ceux-ci
EP2097416B1 (fr) 2006-12-18 2012-09-12 Amgen, Inc Composés d'azaquinolone possédant une activité inhibitrice de prolyl hydroxylase, compositions et utilisations correspondantes
US8048894B2 (en) 2007-04-18 2011-11-01 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
WO2008130508A1 (fr) 2007-04-18 2008-10-30 Amgen Inc. Dérivés d'indanone qui inhibent la prolyle hydroxylase
AU2008248165B2 (en) 2007-05-04 2011-12-08 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
AU2008248234B2 (en) 2007-05-04 2011-02-03 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
TWI437994B (zh) 2007-09-17 2014-05-21 Abbvie Bahamas Ltd 抗感染劑及其用途
EP2252619B1 (fr) 2008-01-11 2013-10-09 Fibrogen, Inc. Dérivés d'isothiazole-pyridine en tant que modulateurs de l'activité du hif (facteur inductible par l'hypoxie)
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
AU2009225869B2 (en) * 2008-03-18 2014-01-23 Merck Sharp & Dohme Llc Substituted 4-hydroxypyrimidine-5-carboxamides
PT2294066E (pt) 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
GB0809262D0 (en) 2008-05-21 2008-06-25 Isis Innovation Assay
US20110098324A1 (en) * 2008-06-25 2011-04-28 Brackley Iii James A Prolyl hydroxylase inhibitors
US8217043B2 (en) 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
US20110144167A1 (en) * 2008-08-25 2011-06-16 Smithkline Beecham Corporation Prolyl Hydroxylase Inhibitors
EP2370422B1 (fr) 2008-11-14 2019-06-05 Fibrogen, Inc. Dérivés de thiochromène utiles en tant qu'inhibiteurs de l'hydroxylase hif
WO2010093727A1 (fr) 2009-02-10 2010-08-19 Janssen Pharmaceutica Nv Quinazolinones en tant qu'inhibiteurs de prolyle hydroxylase
CN102361557A (zh) * 2009-03-26 2012-02-22 Mapi医药公司 制备阿格列汀的方法
EP3144299A1 (fr) * 2009-05-05 2017-03-22 Cambria Pharmaceuticals, Inc. Pyrimidine-2, 4, 6-triones a utiliser dans le traitement de sclerose laterale amyotrophique
ME01858B (me) * 2009-07-17 2014-12-20 Japan Tobacco Inc Jedinjenje triazolopiridina i njegovo dejstvo kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina
TWI500623B (zh) * 2009-10-13 2015-09-21 Torrent Pharmaceuticals Ltd 新穎稠合噻唑及噁唑嘧啶酮
PT2492266E (pt) 2009-10-21 2015-11-18 Daiichi Sankyo Co Ltd Derivado de 5-hidroxipirimidino-4-carboxamida
NZ600400A (en) 2009-11-06 2014-09-26 Aerpio Therapeutics Inc Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
CN103068821B (zh) 2010-08-13 2015-02-25 詹森药业有限公司 作为脯氨酰羟化酶抑制剂的4-氨基喹唑啉-2-基-1-吡唑-4-羧酸化合物
EP2670750B1 (fr) 2011-02-02 2016-09-14 Fibrogen, Inc. Dérivés de naphthyridine en tant qu'inhibiteurs d'un facteur inductible par l'hypoxie
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
NO2686520T3 (fr) 2011-06-06 2018-03-17
MX2013014310A (es) 2011-06-06 2014-01-23 Akebia Therapeutics Inc Compuestos y composiciones para estabilizar el factor-2 alfa inducible por hipoxia como un metodo para tratar el cancer.
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
WO2013043621A1 (fr) 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Pyrimidines substituées
WO2013043624A1 (fr) 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Pyrimidines substituées
WO2013040789A1 (fr) * 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Pyrimidines substituées
WO2013040790A1 (fr) * 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Pyrimidines substituées
CN102432549B (zh) * 2011-09-28 2014-09-03 南通市华峰化工有限责任公司 一种抑制血管生成、肿瘤发生和增殖疾病的药物中间体1,3-二环己基巴比妥酸的制备方法
BR112014009910B1 (pt) 2011-10-25 2020-06-30 Janssen Pharmaceutica N.V. sal di-hidrato de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico, composição farmacêuticae pomada tópica
US20140309256A1 (en) * 2011-11-09 2014-10-16 Fibrogen, Inc. Therapeutic Method
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
SG11201500720WA (en) 2012-07-30 2015-04-29 Taisho Pharmaceutical Co Ltd Partially saturated nitrogen-containing heterocyclic compound
CN103146720B (zh) * 2013-03-01 2014-12-03 河北博伦特药业有限公司 一种具有高转化率的反式-4-羟基-l-脯氨酸羟化酶改造基因及其应用
NZ753905A (en) 2013-06-13 2020-07-31 Akebia Therapeutics Inc Compositions and methods for treating anemia
EP3066098A1 (fr) * 2013-11-08 2016-09-14 Bayer Pharma Aktiengesellschaft Uraciles substitués et leur utilisation
CN105873919A (zh) 2013-11-08 2016-08-17 拜耳医药股份有限公司 作为类糜蛋白酶抑制剂的取代的尿嘧啶
TWI788702B (zh) 2013-11-15 2023-01-01 美商阿克比治療有限公司 {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途
JP5975122B2 (ja) * 2014-01-29 2016-08-23 大正製薬株式会社 ［（４−ヒドロキシ−２−オキソ−１，２，５，６−テトラヒドロ−３−ピリジニル）カルボニル］グリシン化合物の結晶形及びそれらの製造方法
CN106232120B (zh) * 2014-02-19 2021-01-08 爱尔皮奥治疗有限公司 制备n-苄基-3-羟基-4-取代的-吡啶-2-(1h)-酮的方法
CN104151254A (zh) * 2014-07-25 2014-11-19 南通市华峰化工有限责任公司 一种制备1，3-双环己基巴比妥酸的方法
AU2015311333B2 (en) 2014-09-02 2017-11-16 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
WO2016054806A1 (fr) * 2014-10-10 2016-04-14 Merck Sharp & Dohme Corp. Pyridines substituées utilisées comme inhibiteurs de la hif prolyl hydroxylase
WO2016054805A1 (fr) * 2014-10-10 2016-04-14 Merck Sharp & Dohme Corp. Pyrimidines substituées utilisées comme inhibiteurs de hif prolyl hydroxylase
JP2018039733A (ja) * 2014-12-22 2018-03-15 株式会社富士薬品 新規複素環誘導体
AU2016209126A1 (en) 2015-01-23 2017-08-10 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
CN106146395B (zh) 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
US10401548B2 (en) * 2015-09-24 2019-09-03 Intel Corporation Integrated antenna with display uniformity
WO2017066454A2 (fr) 2015-10-14 2017-04-20 X-Therma, Inc. Compositions et procédés permettant de réduire la formation de cristaux de glace
JP6325139B2 (ja) * 2016-03-02 2018-05-16 ネルファルマ・エッセ・エッルレ・エッレ カルムスチンの安全で効率的な製造方法
CN108484598B (zh) 2017-05-09 2021-03-02 杭州安道药业有限公司 吲哚嗪衍生物及其在医药上的应用
CN111518038B (zh) * 2017-05-26 2022-04-05 深圳市塔吉瑞生物医药有限公司 一种取代的嘧啶三酮化合物及包含该化合物的组合物及其用途
CA3112277A1 (fr) 2017-09-15 2019-03-21 Crystal Pharmaceutical (Suzhou) Co., Ltd. Forme cristalline de gsk1278863 et son procede de preparation et son utilisation pharmaceutique
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
CN109134356A (zh) * 2018-06-18 2019-01-04 苏州盖德精细材料有限公司 一种中间体2-氨基吡啶-4-甲醇的制备方法
WO2020102302A1 (fr) 2018-11-15 2020-05-22 Teva Pharmaceuticals International Gmbh Formes solides de daprodustat et leurs procédés de préparation
CN113811530B (zh) * 2019-07-03 2022-07-19 南京明德新药研发有限公司 作为糜酶抑制剂的嘧啶酮类化合物及其应用
WO2021031102A1 (fr) * 2019-08-20 2021-02-25 深圳仁泰医药科技有限公司 Forme cristalline de daprodustat, son procédé de préparation et son utilisation
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
US20230218592A1 (en) 2020-04-20 2023-07-13 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
JP2023532223A (ja) 2020-06-19 2023-07-27 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド ダプロデュスタットを含んでなる処方物
WO2022135534A1 (fr) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 Composé bicyclique azoté substitué et son utilisation
WO2022150623A1 (fr) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Composés et composition pour traiter l'anémie
WO2022179967A1 (fr) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat pour le traitement de la covid-19 chez un sujet hospitalisé
TW202313072A (zh) 2021-05-27 2023-04-01 美商凱立克斯生物製藥股份有限公司 檸檬酸鐵之兒科調配物
CA3221427A1 (fr) 2021-06-18 2022-12-22 Nicholas FALCO Nouveau procede de fabrication de daproducstat et ses precurseurs
IT202100020591A1 (it) 2021-07-30 2023-01-30 Dipharma Francis Srl Preparazione di un intermedio di un agente per il trattamento dell'anemia
IT202100020609A1 (it) 2021-07-30 2023-01-30 Dipharma Francis Srl Metodo di preparazione di agente adatto per il trattamento dell'anemia
IT202200008693A1 (it) 2022-04-29 2023-10-29 Dipharma Francis Srl Metodo per la preparazione e la purificazione di un agente per il trattamento dell'anemia
WO2023006986A1 (fr) 2021-07-30 2023-02-02 Dipharma Francis S.R.L. Procédé de préparation et de purification d'un agent approprié pour le traitement de l'anémie
WO2024022998A1 (fr) 2022-07-26 2024-02-01 Inke, S.A. Procédé de préparation de daprodustat et co-cristaux de celui-ci
GB202211231D0 (en) 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0424064T3 (da) 1989-10-16 1995-06-26 Chiroscience Ltd Chirale azabicycloheptanoner og fremgangsmåde til fremstilling deraf
DE59401923D1 (de) * 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
AU5316900A (en) * 1999-06-03 2000-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
US6878743B2 (en) * 2001-09-18 2005-04-12 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
CA3094774A1 (fr) * 2001-12-06 2003-07-03 Fibrogen, Inc. Utilisation d'inhibiteur d'hydroxylase prolyl hif pour le traitement destroubles neurologiques
US7180893B1 (en) 2002-03-22 2007-02-20 Juniper Networks, Inc. Parallel layer 2 and layer 3 processing components in a network router
ES2283851T3 (es) * 2002-08-13 2007-11-01 Warner-Lambert Company Llc Derivados de pirimidin-2,4-diona como inhibidores de las metaloproteinasas de matriz.
US8614204B2 (en) * 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
BRPI0411055B1 (pt) * 2003-06-06 2018-08-21 Fibrogen, Inc Compostos de heteroarilas contendo nitrogênio. seus usos no aumento da eritropoietina endógena, composição farmacêutica que os compreende e método in vitro de inibição da atividade da enzima hidrolase
JP2007505121A (ja) * 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
CA2559302C (fr) * 2004-03-15 2012-06-19 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyle peptidase
JP2007277096A (ja) 2004-07-15 2007-10-25 Astellas Pharma Inc フェネチルニコチンアミド誘導体含有医薬
US7718624B2 (en) * 2004-09-01 2010-05-18 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
US20060276477A1 (en) * 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia
US20090176776A1 (en) * 2005-10-21 2009-07-09 University Of Alabama At Birmingham Small molecule inhibitors of hiv-1 capsid assembly
US7713986B2 (en) * 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) * 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
AR061570A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto
CL2007001829A1 (es) * 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
US20090011051A1 (en) 2006-09-28 2009-01-08 Roth Mark B Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds
US20100003190A1 (en) * 2006-12-08 2010-01-07 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN)
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
CA3112277A1 (fr) 2017-09-15 2019-03-21 Crystal Pharmaceutical (Suzhou) Co., Ltd. Forme cristalline de gsk1278863 et son procede de preparation et son utilisation pharmaceutique
WO2020102302A1 (fr) 2018-11-15 2020-05-22 Teva Pharmaceuticals International Gmbh Formes solides de daprodustat et leurs procédés de préparation

Also Published As

Publication number Publication date
JP2009541351A (ja) 2009-11-26
EP2037922A2 (fr) 2009-03-25
US20140024666A1 (en) 2014-01-23
JO2934B1 (en) 2015-09-15
JP5203361B2 (ja) 2013-06-05
WO2007150011A8 (fr) 2008-07-10
CA2655491A1 (fr) 2007-12-27
AR061570A1 (es) 2008-09-03
ES2453100T3 (es) 2014-04-04
BRPI0713446A2 (pt) 2012-03-06
WO2007150011A2 (fr) 2007-12-27
TW200815364A (en) 2008-04-01
KR101411816B1 (ko) 2014-06-24
US20100113444A1 (en) 2010-05-06
US20140336383A1 (en) 2014-11-13
EP2037922B9 (fr) 2017-08-23
US10336711B2 (en) 2019-07-02
US11643397B2 (en) 2023-05-09
PT2037922E (pt) 2014-04-14
US8815884B2 (en) 2014-08-26
US20130072487A1 (en) 2013-03-21
CN101505752B (zh) 2012-12-05
IL196070A (en) 2015-05-31
AU2007260837A1 (en) 2007-12-27
BRPI0713446B1 (pt) 2019-10-29
US8557834B2 (en) 2013-10-15
US20150315157A1 (en) 2015-11-05
PE20080209A1 (es) 2008-05-15
US20200157055A1 (en) 2020-05-21
MX2009000165A (es) 2009-01-23
NO20090202L (no) 2009-03-23
PL2037922T3 (pl) 2014-06-30
AU2007260837B2 (en) 2013-07-04
HK1130671A1 (en) 2010-01-08
BRPI0713446B8 (pt) 2021-05-25
NO342019B1 (no) 2018-03-12
DK2037922T3 (en) 2014-03-24
SG174775A1 (en) 2011-10-28
IL196070A0 (en) 2009-09-01
US20210347740A1 (en) 2021-11-11
KR20090030321A (ko) 2009-03-24
US20160297772A1 (en) 2016-10-13
EA018220B1 (ru) 2013-06-28
US20230227414A1 (en) 2023-07-20
WO2007150011A3 (fr) 2008-03-27
CA2655491C (fr) 2016-09-06
HRP20140306T1 (hr) 2014-05-09
EP2037922B1 (fr) 2014-01-22
TWI394747B (zh) 2013-05-01
EP2037922A4 (fr) 2012-08-22
EA200970050A1 (ru) 2009-06-30
SI2037922T1 (sl) 2014-04-30
US20180305323A1 (en) 2018-10-25
CN101505752A (zh) 2009-08-12
US8324208B2 (en) 2012-12-04
NZ573698A (en) 2012-02-24
MY149861A (en) 2013-10-31
CR10534A (es) 2009-03-20
UA100225C2 (uk) 2012-12-10
US10035779B2 (en) 2018-07-31
ZA200810602B (en) 2010-10-27

Similar Documents

Publication Publication Date Title
MA30526B1 (fr) Inhibiteurs de prolyle hydroxylase
MA30358B1 (fr) Quinazolines pour l'inhibition de pdk1
MA27561A1 (fr) Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
MX2009007548A (es) Derivados de glicina n-sustituidos: inhibidores de hidroxilasa.
TNSN05249A1 (fr) Benzopyrannes utiles pour le traitement d'etats inflammatoires
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA30198B1 (fr) Inhibiteurs de la protease ns3 du vhc
MA30428B1 (fr) Derives de dihydropyrazolopyrimidinones
MA31001B1 (fr) Quinazolines destines a l'inhibition de pdk
EA201000915A1 (ru) Ингибиторы пролилгидроксилазы
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MXPA05012596A (es) Inhibidores de quinasa, de indazol, bencisoxazol y bencisotiazol.
YU84603A (sh) Novi inhibitori tirozin kinaze
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
TNSN06370A1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
ATE554087T1 (de) Neue kinaseinhibitoren
EA200700189A1 (ru) Производные хиназолина в качестве ингибиторов parp
MA29757B1 (fr) Peptides macrocycliques en tant qu'inhibiteurs de la protease ns3 du vhc
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
MA29639B1 (fr) Derives de cyclohexylamine isoquinolone en tant qu'inhibiteurs de la rhokinase.